The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...
Investor's Business Daily on MSN
Boston Scientific just took a 9% header. Why analysts are still bullish
Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.
Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.
CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...
In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...
Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans.
Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...
Boston Scientific (BSX) stock tumbled 9% to two-year lows after Watchman trial data revealed stroke concerns and Raymond ...
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results